Skip to content

Structure Therapeutics

US · GPCR #2815 by market cap Listed 2023
16.13 -0.99 -5.78%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 16.84 -1.64%
After-hours 16.69 +3.47%
Overnight 17.12 0.00%
56.6316.1316.132026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on GPCR?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -60.6% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D

How much profit the business keeps from each dollar of sales and capital.

Return on equity -11.9% Better than 19%
Return on invested capital -11.8% Better than 16%
Momentum F

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -67.1% Better than 1%
6-month return -58.8% Better than 5%
12-month return (ex latest month) -36.1% Better than 7%
Distance below 52-week high 83.0% Better than 2%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 24.8x Better than 99%
Debt to assets 0.4% Better than 96%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 542.7% Better than 100%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -19.35%
1M -29.50%
3M -68.07%
6M -56.25%
YTD -76.81%
1Y -53.03%
3Y -69.83%

Key statistics

Price & volume

Prev close
17.12
Open
16.73
Day range
16.06 - 17.08
Avg price
16.43
Volume
786.24K
Turnover
12.92M
Amplitude
5.96%
52-week range
16.06 - 94.90

Valuation

P/E
-6.72
P/E (TTM)
-4.14
P/B
0.95
EPS
-2.40
Net profit
-171.82M
Net assets
1.22B

Share structure

Market cap
1.15B
Float cap
894.95M
Shares out
71.59M
Float shares
55.48M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2023-02-03
52-week range 0% of range
16.06 94.90

83.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-22.22M net over the window

Short interest

Shares short
5.93M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Structure Therapeutics (GPCR)?

Structure Therapeutics last traded at 16.13. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Structure Therapeutics's market cap?

About 1.15B.

What is the P/E ratio of Structure Therapeutics?

The trailing twelve-month P/E is -4.14. The Valuation tab shows it against the stock's own five-year range.

Does Structure Therapeutics pay a dividend?

Structure Therapeutics does not currently pay a regular dividend.

Is Structure Therapeutics a buy according to analysts?

The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 103.67, which implies 542.7% upside from the current price. This is not investment advice.

What is Structure Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Structure Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Structure Therapeutics discussion 0 comments

Add a comment